Form 4 for IRD Opus Genetics, Inc.
Accepted 2024-01-22 00:00:00 ET · period of report 2024-01-18 · accession 0001140361-24-003191 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-22 | 2024-01-18 | IRD | Zaremba Rabourn Amy | SVP of Fin | A - Grant | $0.00 | +40.0K | 82.7K | +94% | $0 |
| D | 2024-01-22 | 2024-01-18 | IRD | Zaremba Rabourn Amy | SVP of Fin | A - Grant | $0.00 | +60.0K | 60.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-18 | A | A | 40,000 | $0.00 | 82,658 | D | — | — | (F1) Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of January 18, 2024. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2024-01-18 | A | A | 60,000 | $0.00 | 60,000 | D | $2.77 · — to 2034-01-17 | 60,000 Common Stock | (F2) The option will vest with respect to 15,000 shares on January 18, 2025, with the balance vesting quarterly in twelve equal installments thereafter at the end of each quarter. |